Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Accumulated Expenses (2020 - 2026)

Bioventus filings provide 6 years of Accumulated Expenses readings, the most recent being $130.2 million for Q4 2025.

  • On a quarterly basis, Accumulated Expenses fell 4.15% to $130.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $130.2 million, a 4.15% decrease, with the full-year FY2025 number at $130.2 million, down 4.15% from a year prior.
  • Accumulated Expenses hit $130.2 million in Q4 2025 for Bioventus, up from $119.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $146.8 million in Q3 2022 to a low of $89.7 million in Q2 2021.
  • Median Accumulated Expenses over the past 5 years was $119.2 million (2023), compared with a mean of $119.7 million.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 49.08% in 2021 and later fell 18.8% in 2025.
  • Bioventus' Accumulated Expenses stood at $131.5 million in 2021, then decreased by 15.14% to $111.6 million in 2022, then grew by 7.37% to $119.8 million in 2023, then rose by 13.43% to $135.9 million in 2024, then dropped by 4.15% to $130.2 million in 2025.
  • The last three reported values for Accumulated Expenses were $130.2 million (Q4 2025), $119.4 million (Q3 2025), and $113.7 million (Q2 2025) per Business Quant data.